AKBA - Company ID 0001517022
The table below shows Akebia Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $155.55M | $162.64M | $166.44M | $137.31M | $113.37M | $34.02M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $53.51M | $62.54M | $66.22M | $72.81M | $61.54M | $32.17M |
| Inventory | $13.02M | $13.00M | $18.64M | $16.71M | $19.73M | $20.49M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $229.55M |
| $243.48M |
| $258.34M |
| $234.66M |
| $203.78M |
| $100.12M |
| Property, plant & equipment | $1.51M | $956.00K | $1.47M | $1.71M | $1.90M | $2.53M |
| Goodwill | $59.04M | $59.04M | $59.04M | $59.04M | $59.04M | $59.04M |
| Total assets | $349.66M | $362.52M | $364.15M | $345.60M | $310.19M | $207.14M |
| Accounts payable | $9.42M | $8.39M | $10.09M | $11.55M | $12.66M | $13.49M |
| Total current liabilities | $160.87M | $173.88M | $133.38M | $118.72M | $91.23M | $65.71M |
| Long-term debt | $24.75M | $36.40M | $47.64M | $47.06M | $46.51M | $38.35M |
| Total liabilities | $324.64M | $335.14M | $322.56M | $316.37M | $285.60M | $257.54M |
| Retained earnings | -$1.70B | -$1.69B | -$1.67B | -$1.67B | -$1.67B | -$1.66B |
| Total equity | $25.02M | $27.38M | $41.59M | $29.22M | $24.58M | -$50.40M |